Previous studies have reported that silencing PPP2R1B enhances 5-FU resistance (Zhang et al., 2015), and PPP2R1B overexpression increases the sensitivity of tongue squamous cell carcinoma and esophageal cancer cells to docetaxel and cisplatin, respectively by acting as an AKT phosphatase (Hamano et al., 2011; Cui et al., 2020). The gene discussed is PPP2R1B; the disease is esophageal cancer.